newsHER2-đương tính Ung thư vúneoadjuvant chemotherapy
MRI-Guided Personalization of Chemotherapy for HER2-Positive Breast Cancer: Insights from the TRAIN-3 Trial
By MedXY|Mar 2, 2026
The TRAIN-3 study reveals that using MRI to monitor treatment response allows for shorter chemotherapy durations in HER2-positive breast cancer patients, achieving high 3-year event-free survival while significantly reducing toxicity and im
